IRDAI's 2024 Corporate Governance Master Circular: the board duties every insurer must meet

India's insurers manage crores of policyholder money on a fiduciary basis, and on 22 May 2024 the Insurance Regulatory and Development Authority of India (IRDAI) rewrote the rulebook for how their boards must behave. The Master Circular on Corporate Governance for Insurers, 2024 (Ref: IRDAI/F&I/CIR/MISC/82/5/2024) turned the broad principles of the parent regulations into hard, checkable duties, with a compliance deadline of 30 June 2024. This deep dive explains it clause by clause, with the exact thresholds every insurer's board now has to meet.

The Rule / Product

The circular was issued under three sources of power: Section 34 of the Insurance Act, 1938, Section 14 of the IRDA Act, 1999, and Regulation 12 of the IRDAI (Corporate Governance for Insurers) Regulations, 2024. Those Regulations were notified on 21 March 2024, and the Master Circular of 22 May 2024 exists to spell out the "operational and procedural aspects" for adoption by every insurer. It was approved by the Competent Authority and signed by G R Surya Kumar, Chief General Manager.

The scope is deliberately wide. Per clause 3 of the circular, it applies to all insurers except a foreign company engaged in re-insurance business through a branch established in India. That single carve-out aside, every life, general, standalone health and reinsurance company registered with IRDAI is bound by it. The circular became effective on issuance, but insurers were given until 30 June 2024 to bring themselves into compliance, and up to six months from the date of issue (clause 4.10) to reconstitute the mandatory committees where changes were needed.

At its heart, the circular sets out an accountability chain across three tiers named in clause 1: the Board of Directors, Senior Management, and Key Persons in Control Functions. Clause 1 states plainly that the framework must ensure "that decision-making powers are not overly centralized" -- the entire document is engineered against the single-strongman insurer.

The board rules start with composition. Clause 2.1 requires a minimum of three independent directors, an optimum mix of independent and non-executive directors, and at least one woman director as mandated by Section 149 of the Companies Act, 2013. Clause 2.1(b) fixes the board quorum at one-third of total board strength or three directors, whichever is higher. It is "good practice" under clause 2.1(f) for the chair of the board to be a non-executive member who does not chair any board committee, and any chairperson appointment needs prior approval of the Competent Authority (Form A, B and C, Annexure 1).

Clause 2.4 imposes fit-and-proper ceilings. No non-executive director, including the chairperson, may continue beyond the age of 75. An independent director may serve a term of up to five consecutive years, is eligible for a second term only on a special resolution, may not hold office for more than two consecutive terms, and becomes re-eligible only after a cooling-off of at least three years. A managing director, chief executive officer or whole-time director may not hold the post for more than 15 continuous years, with a cooling-off of at least one year thereafter and a hard retirement age of 70. Where such a person is appointed by a promoter or major shareholder, the ceiling drops to 12 continuous years, extendable to 15 only with the Authority's specific permission.

Then comes the committee architecture -- the operational spine of the circular.

Clause 4.9(a) requires the mandatory committees -- except the Nomination and Remuneration, CSR and With-Profits committees -- to meet at least four times a year, with no more than four months between two successive meetings. Committee quorum under clause 4.9(b) is two members or one-third of members, whichever is greater, and where an independent director must chair a committee, the meeting cannot be held in that person's absence. An Ethics Committee is described in clause 4.8 but is not mandatory.

Below the board sit the Key Management Persons and control functions. Clause 2.5 requires the independence of five control functions -- compliance, risk, audit, actuarial and secretarial. Clause 6 requires a Chief Compliance Officer appointed for a minimum fixed tenure of three years, reporting directly to the Board or a board committee and carrying no reporting relationship with any business vertical. The parent Regulation 5(7)(c) required any Key Management Person holding two conflicting roles to be reorganised before 1 April 2025.

Why It Matters

Governance failures in insurance are not abstract. An insurer holds long-dated promises -- a term policy bought in 2024 may pay out in 2064 -- so the quality of the board that oversees reserving, investment and claims determines whether a claim is honoured decades later. The circular's clause 1 anchors this: because insurers "accept public liabilities", their relationship with stakeholders is "fiduciary with enhanced responsibility". Understanding what your insurer's Appointed Actuary and Risk Management Committee actually do is therefore a policyholder concern, not a boardroom triviality.

For a policyholder, three of the circular's committees matter most. The Investment Committee (clause 4.2) must meet at least once a quarter to protect policyholders' funds; the Risk Management Committee (clause 4.3) must review the insurer's solvency position on a regular basis and run the anti-fraud framework; and the Policyholder Protection committee (clause 4.4) must review every Insurance Ombudsman or Consumer Forum award left unimplemented for more than 30 days and escalate it to the board. If you have ever calculated your own cover need on a term insurance premium calculator and wondered who guards that money for the next 40 years, clause 4.2 is the answer.

There is also a direct transparency dividend. Clause 8.1 requires the board to disclose, in the annual accounts, the incurred-claim, commission and expense ratios, the actual versus required solvency margin, and -- for life insurers -- the persistency ratio of policies sold. Clause 8.2 requires each insurer to publish, in the Directors' Report, the number of board and committee meetings held and the attendance of each director. A prospective buyer comparing two health insurers can read the incurred-claim ratio straight from these mandated disclosures before running the numbers on a health insurance premium calculator.

Accountability is enforced through a certificate. Clause 2.2(e) requires each insurer to file, within three months of the financial year-end (that is, before 30 June each year), a certificate signed by the CEO confirming compliance. Non-compliance is therefore a documented, dated failure rather than a matter of interpretation.

Worked Numbers

Because the circular is built from thresholds, its obligations can be modelled precisely. Consider a hypothetical private life insurer, "Model Life", with a 12-member board and a three-year average net profit of Rs 500 crore.

Board quorum first. Clause 2.1(b) sets the quorum at one-third of 12, which is 4, or three directors, whichever is higher -- so 4 directors must attend for a valid board meeting. The board must contain at least 3 independent directors (clause 2.1) and at least 1 woman director under Section 149 of the Companies Act, 2013.

Now the mandatory CSR spend. Clause 4.6(c), reading in Section 135(5) of the Companies Act, requires the board to spend not less than 2% of the three-year average net profit on CSR activities. On a Rs 500 crore average, that is a minimum of Rs 10 crore for the year -- and clause 4.6(d)(v) bars that spend from being charged to the policyholders' account.

Committee remuneration is capped too. Clause 9.1(d), which applies to private-sector insurers only, states that total remuneration shall not exceed Rs 30 lakh per annum for each non-executive director, and clause 9.1(e) bars any share-linked benefits for them. If Model Life has 5 non-executive directors each paid at the ceiling, its maximum non-executive remuneration bill is Rs 1.5 crore a year, before sitting fees.

The table below pulls these worked figures together.

A second worked point concerns tenure arithmetic that boards had to complete before 30 June 2024. Under clause 2.4, any non-executive director already aged 75 on 22 May 2024, and any independent director who had already completed two consecutive terms by that date, had to be replaced by 30 June 2024. A promoter-appointed CEO who had already served 12 years by 22 May 2024 likewise had to be succeeded by 30 June 2024 unless the Authority permitted continuance up to the 15-year outer limit -- a 39-day compliance window, not a glide path.

Pitfalls

The circular is full of adjacent rules that trap boards which read only the headline. The most common traps flow from the fine print of composition and tenure.

The first trap is the chairperson who also chairs a committee. Clause 2.1(f) treats a non-executive chair who chairs no committee as good practice, and clause 4.1(a) separately bars the chair of the board from even being a member of the Audit Committee. A board that lets a single dominant chair sit atop both the board and the Audit Committee breaches the letter of clause 4.1(a).

The second trap is one independent director wearing two committee hats. Clause 4.3(d) requires the Risk Management Committee to be chaired by an independent director who is specifically not the chair of the Audit Committee. Appointing the same well-regarded independent director to chair both -- a natural temptation on a small board with only 3 independent directors -- is a direct violation.

The third trap is quorum by warm bodies. Clause 4.9(b) is not satisfied merely by two members turning up: where an independent director is mandated on a committee, at least one such independent director (or the alternate) must be present, and where the independent director must chair the committee, the meeting cannot proceed at all in that person's absence. A quorate-looking Risk Management Committee meeting held without its independent chair is a nullity.

The fourth trap is the missing woman director and the ageing board. Section 149 of the Companies Act, 2013, imported through clause 2.1(h), requires at least one woman director on every insurance company's board, and clause 2.4(a) forbids any non-executive director continuing past 75. Boards that fixated on the committee reshuffle sometimes missed that these are standing conditions, not one-time 2024 checks.

The fifth trap is treating the Chief Compliance Officer as a rotating role. Clause 6(c) fixes a minimum tenure of three years and, crucially, clause 6(d) bars any reporting line to a business vertical. An insurer that parks compliance under its chief of sales, or churns the CCO annually, defeats the independence the clause is designed to create.

The final trap is charging CSR to policyholders. Clause 4.6(d)(v) is explicit that CSR expenditure shall not be charged to the policyholders' account, and clause 4.6(d)(iv) keeps CSR out of the Expenses of Management ceilings under Sections 40B and 40C of the Insurance Act. Mixing these buckets both breaches the circular and inflates the cost you ultimately pay through your premium.

FAQ

When did the IRDAI Corporate Governance Master Circular 2024 take effect, and who does it cover?

It was issued on 22 May 2024 (Ref: IRDAI/F&I/CIR/MISC/82/5/2024), became effective on issuance, and set a compliance deadline of 30 June 2024. Per clause 3, it applies to all insurers except a foreign company doing re-insurance business through a branch established in India.

How many independent directors must an insurer's board have?

Clause 2.1(a) sets a floor of three independent directors and requires an optimum mix of independent and non-executive directors. Under Section 149 of the Companies Act, 2013 (clause 2.1(h)), there must also be at least one woman director on the board.

What are the mandatory board committees under the circular?

Six are mandatory for all insurers: the Audit Committee (4.1), Investment Committee (4.2), Risk Management Committee (4.3), Policyholder Protection, Grievance Redressal and Claims Monitoring Committee (4.4), Nomination and Remuneration Committee (4.5) and Corporate Social Responsibility Committee (4.6). Life insurers must additionally constitute a With-Profits Committee (4.7). The Ethics Committee (4.8) is not mandatory.

How long can a CEO or managing director serve an insurer?

Clause 2.4(c) caps a managing director, CEO or whole-time director at 15 continuous years, with a cooling-off of at least one year and a retirement age of 70. If the person was appointed by a promoter or major shareholder, clause 2.4(d) lowers the cap to 12 continuous years, extendable to 15 only with the Authority's specific permission.

How often must the key committees meet?

Clause 4.9(a) requires the mandatory committees -- other than the Nomination and Remuneration, CSR and With-Profits committees -- to meet at least four times a year, with no gap of more than four months between successive meetings. The Investment Committee must meet at least once a quarter under clause 4.2(h).

Does the Rs 30 lakh remuneration cap apply to all insurers?

No. Clause 9 applies to private-sector insurers only. Within that scope, clause 9.1(d) caps total remuneration at Rs 30 lakh per annum for each non-executive director, and clause 9.1(e) bars any share-linked benefits for them.

How does an insurer prove it has complied?

Clause 2.2(e) requires each insurer to file, within three months of the financial year-end -- that is, before 30 June each year -- a certificate signed by the CEO confirming compliance with the circular, in the format prescribed in the Master Circular on Submission of Returns.